ErasaVir intends to become a part of people’s lives globally: Anupam Dokeniya, Co-Founder, CEO, ErasaVir

ErasaVir mouth and nasal sprays are administered directly to the nose, mouth and throat, where they come in direct contact with the virus or bacteria to destroy it and hence eliminate or reduce pathogen load. ErasaVir acts on the pathogens already present in URT, Anupam Dokeniya told Financial

Erasavir, Nasal spray, oral spray, health news, pharma news,
ErasaVir comprises an optimized FFA using proprietary technology that is then formulated using proprietary methods, Anupam said. (Image Credit: Pixabay)

The ongoing coronavirus pandemic has changed how we perceive and react to diseases. Since the beginning of the pandemic, there has been a paradigm shift in treating, diagnosing and preventing diseases especially communicable ailments. now a few experts have created a unique product that acts like a “soap” for your mouth and nose to live an uninterrupted life by protecting against enveloped viruses like SARS-CoV-2, Influenza, and other pathogens. ErasaVir, a product of Palani LLC, USA in collaboration with Strassenburg Pharmaceuticals is inspired by the protective properties of mother’s milk and based on decades of oncology research with a similar class of compounds found in plant-based food substances.

According to the developers of this product, Erasavir ensures complete Upper Respiratory Tract Protection: Both nasal and mouth sprays protect both the routes of entry of the virus. It’s a first-of-its-kind oral and nasal spray that has been proven to be safe and categorized as GRAS (Generally Recognised as Safe) by the USFDA.

Financial reached out to Anupam Dokeniya, Co-Founder, CEO, ErasaVir and he highlighted various aspects of this unique product. Excerpts:

What is ErasaVir? What makes it different from other medical products?

The pandemic has changed much of our behaviour, including how we look at hygiene in relation to harmful pathogens we encounter daily. ErasaVir reimagines and upgrades your hygiene to protect you from some of these pathogens. ErasaVir is Hygiene 2.0

-Erasavir represents the next frontier in personal hygiene

-Proprietary methods used to make the active ingredients and formulations to make final product

-Actives are plant-based food substances

-Both nasal and mouth sprays as a combination

-All ingredients are GRAS (Generally Recognized As Safe)by the United States Food and Drug Agency (USFDA), safe for life-long daily use

-Effective against viruses and bacteria that have envelopes (lipid membranes). ErasaVir kills these harmful pathogens once they enter our Upper Respiratory Tract; pathogens like SARS-CoV-2 and other coronaviruses, Flu viruses, and bacteria families like staphylococcus and streptococcus etc.

-Only brand that protects from both bacteria and virus from inside the body.

The diagram explains the product market fit

It differs from other medical products:

-ErasaVir is based on plant-based food substances

-Life-long daily use without side effects

-It’s a preventive measure to protect against harmful pathogens we encounter in our daily lives

-Only product to cover the oral as well as nasal routes of transmission

-This is a proprietary, branded and patent-pending product that addresses a very crucial need as we go about our daily lives

-Does not require a prescription

-No side effects

-Efficacy proven in an United Nations affiliated lab

Anupam Dokeniya, Co-Founder, CEO, ErasaVir

How does ErasaVir work against enveloped viruses like SARS-CoV-2, Influenza, and other pathogens?

Enveloped pathogens are protected by a fatty coating (lipid membrane). SARS-CoV-2 that causes COVID-19 is one such enveloped virus. Flu viruses are also enveloped viruses that have a lipid membrane. Similarly many common, harmful bacteria (including the streptococcus and staphylococcus families) are also protected by such a membrane.

This fatty coating can be disrupted by Lipid Dissolving Agents (LDAs that are amphipathic – amphipathic described below) like detergents and soaps on contact in presence of aqueous (water) medium.

Fatty coating disruption leads to destruction of the enveloped viruses like SARS-CoV-2 and Flu as well as enveloped bacteria.

Free Fatty Acids (FFAs) are also LDAs and are proven to have amphipathic properties

Some of these FFAs are not only safe but an essential part of our diet. They are also found in mother’s milk and protect babies from pathogens. Numerous studies have shown that FFAs can destroy enveloped viruses and bacteria via their amphipathic properties and in some pathogens through other, highly specific interactions.

FFAs destroy enveloped viruses via their detergent actions (extensive scientific literature and proprietary studies conducted). FFAs are highly amphipathic like detergents

Coronaviruses like SARS-CoV-2 and Flu are enveloped pathogens that are inactivated by LDAs

ErasaVir comprises an optimized FFA using proprietary technology that is then formulated using proprietary methods. This proprietary formulation completely inactivated SARS-CoV-2 in a study conducted at a United Nations affiliated BSL-3 virology lab

Respiratory pathogens enter our body through the nose and throat (called the ‘Upper Respiratory Tract’ or ‘URT’) and incubate there before moving to the lungs (or the ‘Lower Respiratory Tract’ or ‘LRT’) and other organs where it may cause serious damage

ErasaVir mouth and nasal sprays are administered directly to the nose, mouth and throat, where they come in direct contact with the virus or bacteria to destroy it and hence eliminate or reduce pathogen load. ErasaVir acts on the pathogens already present in URT

From this we conclude that ErasaVir can disintegrate viruses and bacteria adhering to the surfaces in URT; hence reducing the pathogen load going to the LRT – leading to much better outcomes and quicker recoveries

Another benefit of using ErasaVir is that if users of ErasaVir are exposed to the respiratory pathogens like coronavirus, they will likely shed fewer viral particles, and may help reduce the spread of the virus to others around them.

An example of how ErasaVir works against one of many enveloped pathogens.

Understanding ‘Amphipathic’

Soap works because its molecules have a ‘water-loving’ (hydrophilic) side and a ‘fat-loving’ (lipophilic) side. When you mix soap and water, the soap molecules break down the grease and germs into smaller particles and its fat-loving hydrophobic parts group together to ‘trap’ these particles. Then, when you rinse with water, the hydrophilic parts of soap are attracted to it, and it washes away the soap and disintegrates grime and germs (fatty substances).

This addresses only SARS-CoV-2 but applies to any pathogens that have a lipid membrane.

Does ErasaVir work against all variants of COVID-19? How and what is its efficacy rate?

ErasaVir works against all variants and mutations of SARS-CoV-2, a coronavirus that causes COVID-19, as well as all other such pathogens with a lipid , membrane and all their mutations and variants. The nucleic acids and the proteins mutate but lipid membranes do not mutate. As long as it’s a lipid membrane, and that’s always the case no matter what variants, ErasaVir is very effective in killing that pathogen.

In an UN affiliated BSL-3 lab, ErasaVir showed 100% efficacy, all the live and viable SARS-CoV-2 virions were “killed” and not able to infect the cells. After treatment with ErasaVir, these viruses were not able to infiltrate any cells.

Who is eligible to use this product? Does it have any side effects?

We do not know anybody who may not be eligible to use ErasaVir but like any other product it’s possible that someone may be allergic to any of the ingredients or have some special medical condition but we are not aware of any. Until we do further studies, we recommend that very young children, possibly below the age 3 years do not use it though we do not anticipate any problem. Babies who are nursing are protected since the mother’s milk contains ingredients that provide this protection. In fact ErasaVir is inspired by the protection provided by mother’s milk to the babies against these pathogens.

We have not seen any side effects. However, with most nasal sprays, generally it may take some getting used to. We have explained the optimal way to use this.

What are your plans in India with respect to ErasaVir? How can it contribute to existing COVID-19 treatments?

Last 6 months, ErasaVir was introduced to doctors across India by Strassenburg Pharmaceuticals, while Palani LLC (the company that invented ErasaVir and owns the brand) worked on further optimizing the formulation. The feedback from the doctors was more than encouraging and many became users of ErasaVir as they understood the science on which ErasaVir is based.

While ErasaVir itself is not a treatment, it has the potential to reduce the need for treatments in situations where it can help users avoid viral and bacterial infections. In situations where individuals are themselves immunocompromised/suffer from chronic conditions or live around someone like that, ErasaVir’s value is even greater. In those cases the user may be able to avoid a great deal of danger, pain, and expense by adding this simple step to their daily routine.

Initially conceived at the start of the pandemic, ErasaVir has evolved into a unique daily hygiene product that addresses a critical need no other product does. Now we plan to make ErasaVir available to as many people in India as possible:

-Go directly to the customers through its ecommerce site

-Reach customers through third party platforms like 1mg, Amazon, Pharmeasy, Sasta Sundar and others

-Strassenburg will distribute to its network of pharmacies all over India and keep up the conversation with the doctors

-Work with other distributors to reach as many physical stores as possible

-Undertake B2B initiatives: Go to hospitals, airlines, corporates, crowded venues so they can protect their customers and employees

-Work with government bodies and NGOs to distribute ErasaVir at cost to those who can’t afford market pricing

-Already in talks to enter international markets

Are you working on introducing other simplified pharma or medical products?

Yes, we are already working on:

-Different versions of ErasaVir with respect to flavors

-Another unique formulation of ErasaVir based on similar ingredients but different technology that still needs to be validated for this particular use

-A series of other consumer health products, both in Poly Unsaturated Fatty Acids and other mechanisms and platforms where our scientific team has worked on for decades

-Some exciting pipeline projects are too early and confidential to disclose at this stage

The ongoing coronavirus pandemic has led to a paradigm shift in the healthcare and pharmaceutical sector and how we perceive and treat diseases? According to you, what could this mean in a post-covid world?

The pandemic has changed our attitude in so many ways and at so many levels. We believe that we are all more careful about health and diseases; making general and preventive health bigger priorities.
That also means protection from pathogens that cause many serious health problems. As this pandemic has become endemic, we also see other pathogens on hiatus coming out to infect us.

ErasaVir intends to become a part of people’s lives globally as we all try to live a healthier life and avoid sickness whenever possible. ErasaVir can help against some of the pathogens that cause diseases. Its parent company (Palani LLC) is working to bring to customers other important consumer health products that are scientifically validated.

Anything else that you would like to add?

We are looking to collaborate and partner with any entity that can help us reach as many people in India and around the world. We are open to both business collaboration as well as those that are non-profit with government bodies and NGOs. ErasaVir is based on scientific principles and the scientific team and advisors has worked in this area for many decades.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.